Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Centocor
- 09 Feb 2019 1-year safety data from 12 ustekinumab registrational trials published in the Drug Safety.
- 19 Oct 2016 Results of pooled safety analysis from 12 Ustekinumab Crohn's Disease and Psoriatic Diseases trials (n=3636), presented at the 24th United European Gastroenterology Week
- 13 Jun 2015 Results of pooled analysis of PSUMMIT I, PSUMMIT II and a phase II trial presented at the 16th Annual Congress of the European League Against Rheumatism.